查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1845957

Sorafenib市场规模：按产品、应用和地区分類的范围和预测

Sorafenib Market Size By Product (Patented Drugs and Generic Drugs), By Application (Kidney Cancer, Liver Cancer, Thyroid Cancer, Other), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

Sorafenib市场规模及预测

预计Sorafenib市场在 2024 年的价值将达到 11.1 亿美元，并在 2031 年达到 12.1 亿美元，2024 年至 2031 年的复合年增长率为 1.21%。

Sorafenib主要用于治疗肾癌、甲状腺癌和肝癌。流行病学研究表明，过去几十年来甲状腺癌的发生率一直在上升。Sorafenib市场报告对市场进行了全面的评估，包括关键细分市场、趋势、市场驱动因素、限制因素、竞争格局以及影响市场的关键因素。

定义全球Sorafenib市场

Sorafenib是一种分子标靶抗癌药物，其作用机制是抑制多种被认为参与细胞增殖（生长）和血管生成（血液供应）的激酶。Sorafenib最初开发用于治疗无法切除的肝细胞癌 (HCC)、进行性肾细胞癌以及对放射性碘治疗无效的局部復发或转移性进行性分化型甲状腺癌患者。

这种口服激酶抑制剂可有效调节多种蛋白激酶和讯号通路，包括讯号传导和转录活化因子3 (STAT3)、血小板衍生生长因子受体 (PDGFR) 和血管内皮生长因子受体2 (VEGFR-2)。Sorafenib也用于治疗肝癌和甲状腺癌。该药物是晚期肝细胞癌 (HCC) 的一线治疗药物。

然而，自2007年获得FDA核准以来，Sorafenib治疗在肿瘤学实践中并未广泛应用。Sorafenib已知有副作用，包括出血、高血压、皮肤毒性、心肌缺血/梗塞、胃肠道穿孔、药物性肝炎和创伤治疗併发症。此外，多项研究发现Sorafenib产生获得性抗药性，降低了其在肿瘤学领域的临床意义。因此，Sorafenib常与其他用于治疗肝细胞癌的细胞毒药物联合治疗使用，产生协同抗癌活性。

全球Sorafenib市场概览

癌症仍然是全球主要死亡原因之一。癌症新发病例数持续成长。癌症是一个重大的公共卫生问题，目前被认为是一种潜在的慢性疾病。早期诊断和治疗的进步显着提高了癌症患者的存活率。

Sorafenib主要用于治疗肾癌、甲状腺癌和肝癌。流行病学调查结果显示，过去几十年来甲状腺癌的发生率持续上升。高所得国家甲状腺癌的发生率显着上升，全球甲状腺癌的年龄标准化发生率上升了约20%。同样，随着肝癌和肾癌患者的快速增长，预计对Sorafenib等抗癌药物的需求也将增加。

科学家们正在尝试挖掘奈米技术的潜力，以提高Sorafenib的靶向性和生物有效性。基于Sorafenib的奈米递送系统能够控制药物释放，进而提高抗肿瘤疗效。同样，各种研究也正在进行中，旨在结合聚合物胶束的应用来增强Sorafenib的抗肿瘤疗效。聚合物奈米颗粒和胶束等技术的发展已被证明有利于药物递送。因此，在预测期内，加强对Sorafenib的研究力度，以提高生物有效性并减少其副作用，对市场而言是一个重要的机会。

然而，获得性抗药性、经济负担、副作用等诸多因素限制了癌症患者从Sorafenib中获得健康益处。高昂的价格也是限制Sorafenib使用的主要因素之一。人们认为，Sorafenib的高昂价格与其带来的实质益处不符。

此外，已知Sorafenib会对接受该药物治疗的癌症患者产生多种副作用，因此製药公司正忙于开发新药和药物组合，以期在未来取代Sorafenib。新治疗方法的开发对Sorafenib的销售构成了严峻挑战。

目录

第一章 引言

  • 市场定义
  • 市场区隔
  • 调查时间表
  • 先决条件
  • 限制

第二章调查方法

  • 资料探勘
  • 二次调查
  • 初步调查
  • 专家建议
  • 品质检查
  • 最终审核
  • 数据三角测量
  • 自下而上的方法
  • 自上而下的方法
  • 调查流程

第三章执行摘要

  • 市场概况
  • 全球Sorafenib市场区域分析（CAGR）
  • 全球Sorafenib产品市场
  • 全球Sorafenib市场（按应用）
  • 未来市场机会
  • 全球市场区隔

第四章 市场展望

  • Sorafenib尼全球市场前景
  • 市场驱动因素
    • 癌症患者增加
  • 市场限制
    • 阻碍更多患者受益于Sorafenib的因素
    • Sorafenib相关的健康风险
  • 市场机会
    • 正在进行的研究旨在开发有效的Sorafenib製剂
  • 市场挑战
    • Sorafenib销售下滑
    • 新型替代药物的出现
  • COVID-19 对Sorafenib市场的影响

第五章 按产品分類的市场

  • 概述
  • 专利药品
  • 学名药

第六章 按应用分類的市场

  • 概述
  • 肾癌
  • 肝癌
  • 甲状腺癌
  • 其他的

第七章 区域市场

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 其他亚太地区
  • 世界其他地区
    • 中东和非洲
    • 拉丁美洲

第八章竞争格局

  • 概述
  • 企业市场排名分析

第九章：公司简介

  • BAYER AG
  • CIPLA
  • NATCO PHARMA
  • HETERO HEALTHCARE
Product Code: 78956

Sorafenib Market Size And Forecast

Sorafenib Market was valued at USD 1.11 Billion in 2024 and is projected to reach USD 1.21 Billion by 2031, growing at a CAGR of 1.21% from 2024 to 2031.

Sorafenib is primarily used in the treatment of renal cancer (kidney cancer), thyroid cancer, and liver cancer. The incidence of thyroid cancer has been increasing over the last few decades according to epidemiological research findings. Sorafenib Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Sorafenib Market Definition

Sorafenib is a type of molecular targeted cancer drug that works by inhibiting multiple kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply). Sorafenib was initially developed to treat patients with unresectable hepatocellular carcinoma (HCC), patients with advanced renal cell carcinoma, and patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.

The oral kinase inhibitor drug is effective in regulating various protein kinases and signal transduction pathways including the signal transducer and activator of transcription 3 (STAT3), platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptor 2 (VEGFR-2). Sorafenib is also been used in treating liver and thyroid cancer. The drug is used as a first-line treatment for advanced hepatocellular carcinoma (HCC).

However, sorafenib treatment has not been widely adopted into oncology practice since FDA approval in 2007. The drug is known to present several side effects including, hemorrhage, hypertension, dermatologic toxicities, cardiac ischemia and/or infarction, gastrointestinal perforation, drug-induced hepatitis, wound healing complications, and many others. Furthermore, as per various studies it has been observed that sorafenib tends to induce acquired resistance among patients that lowers its clinical importance in the field of cancer. Therefore, sorafenib is used as a combination therapy with other cytotoxic agents for HCC resulting in additive anticancer activity.

Global Sorafenib Market Overview

Cancer remains among the leading causes of death worldwide. The rate of new cancer patients is on a constant rise. Cancer is a significant public health issue and is now considered as a potentially chronic disease. Advancements in the early diagnosis and treatments have significantly improved the cancer survival rate.

Sorafenib is primarily used in the treatment of renal cancer (kidney cancer), thyroid cancer, and liver cancer. The incidence of thyroid cancer has been increasing over the last few decades according to epidemiological research findings. The incidence of thyroid cancer in higher-income countries has been considerably rising and the global age-standardized incidence rate of thyroid cancer increased by approximately 20%. Similarly, with the surge in the liver and kidney cancer cases, the demand for anti-cancer drugs such as sorafenib is expected to rise.

Scientists are unleashing the potential of nanotechnology to improve sorafenib's targetability and bioavailability. Sorafenib-based nano delivery systems allow controlled release of the drug for better anti-tumor effects. Similarly, various research studies are underway incorporating the application of polymer micelles to enhance the antitumor effect of sorafenib. The development of polymer nanoparticles, micelles, and others are proving beneficial for drug delivery. Therefore, it can be suggested that the growing research studies on sorafenib to improve its bioavailability with fewer side effects present a great opportunity for the market over the forecast period.

However, there are several factors such as - acquired resistance, economic burden, adverse reaction, and others are limiting cancer patients to gain health benefits from Sorafenib. Also, the high price has been one of the major factors behind the limited use of Sorafenib. People find the high cost of Sorafenib does not justify enough benefit offered by the drug.

Furthermore, as Sorafenib is known to cause several side effects to the cancer patients receiving the drug, pharmaceutical manufacturing companies are busy developing new drugs or drug combinations that can potentially substitute Sorafenib in the future. The development of new drug treatment approaches poses a strong challenge to the Sorafenib sales

Global Sorafenib Market: Segmentation Analysis

The Global Sorafenib Market is segmented on the basis of Product, Application, and Geography.

Sorafenib Market, By Product

Patented Drugs

Generic Drugs

On the basis of Product, the Global Sorafenib Market has been segmented into Patented Drugs and Generic Drugs. Patented Drugs accounted for the largest market share in 2019. In the case of Sorafenib, in 2008 Bayer was granted a patent over Sorafenib Tosylate (marketed as Nexavar). This crucial drug for kidney and liver cancer was sold at a price that was not affordable in select regions, this factor, along with the general popularity of the drug propelled the growth of generic Sorafenib drugs, particularly in the Asia Pacific region.

Sorafenib Market, By Application

Kidney Cancer

Liver Cancer

Thyroid Cancer

Based on Application, the market is bifurcated into Kidney Cancer, Liver Cancer, Thyroid Cancer, Other. Kidney Cancer accounted for the largest market share in 2019 as Nexavar (sorafenib) has shown to be an effective treatment option for renal cell carcinoma (RCC), or kidney cancer. Researchers from Europe and the United States recently conducted a subgroup analysis of the Treatment Approach in Renal Cancer Global Evaluation Trial. This trial was a large clinical trial evaluating Nexavar in the treatment of advanced RCC.

Sorafenib Market, By Geography

North America

Europe

Asia Pacific

Rest of the world

On the basis of regional analysis, the Global Sorafenib Market is classified into North America, Europe, Asia Pacific, and Rest of the World (RoW). North America dominated the Sorafenib market in 2019 owing to the high prevalence of liver cancer, early diagnosis of liver cancer, availability of cancer therapeutic drugs, high levels of awareness about liver cancer in the region. Also, the well-established health care infrastructure in this region is expected to contribute to the dominant share of North America in the global market.

Key Players

The "Global Sorafenib Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Bayer AG, Cipla, Natco Pharma, and Hetero Healthcare Ltd.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 MARKET DEFINITION
  • 1.2 MARKET SEGMENTATION
  • 1.3 RESEARCH TIMELINES
  • 1.4 ASSUMPTIONS
  • 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

  • 2.1 DATA MINING
  • 2.2 SECONDARY RESEARCH
  • 2.3 PRIMARY RESEARCH
  • 2.4 SUBJECT MATTER EXPERT ADVICE
  • 2.5 QUALITY CHECK
  • 2.6 FINAL REVIEW
  • 2.7 DATA TRIANGULATION
  • 2.8 BOTTOM-UP APPROACH
  • 2.9 TOP DOWN APPROACH
  • 2.1 RESEARCH FLOW

3 EXECUTIVE SUMMARY

  • 3.1 MARKET OVERVIEW
  • 3.2 GLOBAL SORAFENIB MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
  • 3.3 GLOBAL SORAFENIB MARKET, BY PRODUCT (USD MILLION)
  • 3.4 GLOBAL SORAFENIB MARKET, BY APPLICATION (USD MILLION)
  • 3.5 FUTURE MARKET OPPORTUNITIES
  • 3.6 GLOBAL MARKET SPLIT

4 MARKET OUTLOOK

  • 4.1 GLOBAL SORAFENIB MARKET OUTLOOK
  • 4.2 MARKET DRIVERS
    • 4.2.1 RISING PREVALENCE OF PATIENTS SUFFERING WITH CANCER
  • 4.3 MARKET RESTRAINTS
    • 4.3.1 FACTORS PREVENTING MORE PATIENTS BENEFITTING FROM SORAFENIB
    • 4.3.2 HEALTH RISKS ASSOCIATED WITH SORAFENIB
  • 4.4 MARKET OPPORTUNITY
    • 4.4.1 ONGOING RESEARCH STUDIES FOR THE DEVELOPMENT OF EFFECTIVE SORAFENIB FORMULATIONS
  • 4.5 MARKET CHALLENGES
    • 4.5.1 DECREASING SALES OF SORAFENIB
    • 4.5.2 EMERGENCE OF NEW SUBSTITUTE DRUGS
  • 4.6 IMPACT OF COVID-19 ON SORAFENIB MARKET

5 MARKET, BY PRODUCT

  • 5.1 OVERVIEW
  • 5.2 PATENTED DRUGS
  • 5.3 GENERIC DRUGS

6 MARKET, BY APPLICATION

  • 6.1 OVERVIEW
  • 6.2 KIDNEY CANCER
  • 6.3 LIVER CANCER
  • 6.4 THYROID CANCER
  • 6.5 OTHERS

7 MARKET, BY GEOGRAPHY

  • 7.1 OVERVIEW
  • 7.2 NORTH AMERICA
    • 7.2.1 U.S.
    • 7.2.2 CANADA
    • 7.2.3 MEXICO
  • 7.3 EUROPE
    • 7.3.1 GERMANY
    • 7.3.2 U.K.
    • 7.3.3 FRANCE
    • 7.3.4 REST OF EUROPE
  • 7.4 ASIA PACIFIC
    • 7.4.1 CHINA
    • 7.4.2 INDIA
    • 7.4.3 JAPAN
    • 7.4.4 REST OF ASIA PACIFIC
  • 7.5 REST OF WORLD
    • 7.5.1 MIDDLE EAST AND AFRICA
    • 7.5.2 LATIN AMERICA

8 COMPETITIVE LANDSCAPE

  • 8.1 OVERVIEW
  • 8.2 COMPANY MARKET RANKING ANALYSIS

9 COMPANY PROFILES

  • 9.1 BAYER AG
    • 9.1.1 COMPANY OVERVIEW
    • 9.1.2 COMPANY INSIGHTS
    • 9.1.3 SEGMENT BREAKDOWN
    • 9.1.4 PRODUCT BENCHMARKING
    • 9.1.5 SWOT ANALYSIS
  • 9.2 CIPLA
    • 9.2.1 COMPANY OVERVIEW
    • 9.2.2 COMPANY INSIGHTS
    • 9.2.3 SEGMENT BREAKDOWN
    • 9.2.4 PRODUCT BENCHMARKING
    • 9.2.5 SWOT ANALYSIS
  • 9.3 NATCO PHARMA
    • 9.3.1 COMPANY OVERVIEW
    • 9.3.2 COMPANY INSIGHTS
    • 9.3.3 SEGMENT BREAKDOWN
    • 9.3.4 PRODUCT BENCHMARKING
    • 9.3.5 SWOT ANALYSIS
  • 9.4 HETERO HEALTHCARE
    • 9.4.1 COMPANY OVERVIEW
    • 9.4.2 COMPANY INSIGHTS
    • 9.4.3 PRODUCT BENCHMARKING
    • 9.4.4 SWOT ANALYSIS

LIST OF TABLES

  • TABLE 1 GLOBAL SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 2 GLOBAL SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 3 GLOBAL SORAFENIB MARKET, BY GEOGRAPHY, 2020 - 2027 (USD MILLION)
  • TABLE 4 NORTH AMERICA SORAFENIB MARKET, BY COUNTRY, 2020 - 2027 (USD MILLION)
  • TABLE 5 NORTH AMERICA SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 6 NORTH AMERICA SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 7 U.S. SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 8 U.S. SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 10 CANADA SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 11 CANADA SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 13 MEXICO SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 14 MEXICO SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 16 EUROPE SORAFENIB MARKET, BY COUNTRY, 2020 - 2027 (USD MILLION)
  • TABLE 17 EUROPE SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 18 EUROPE SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 19 GERMANY SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 20 GERMANY SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 21 U.K. SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 22 U.K. SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 23 FRANCE SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 24 FRANCE SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 25 REST OF EUROPE SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 26 REST OF EUROPE SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 27 ASIA PACIFIC SORAFENIB MARKET, BY COUNTRY, 2020 - 2027 (USD MILLION)
  • TABLE 28 ASIA PACIFIC SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 29 ASIA PACIFIC SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 30 CHINA SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 31 CHINA SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 32 INDIA SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 33 INDIA SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 34 JAPAN SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 35 JAPAN SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 36 REST OF ASIA PACIFIC SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 37 REST OF ASIA PACIFIC SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 38 REST OF WORLD SORAFENIB MARKET, BY REGION, 2020 - 2027 (USD MILLION)
  • TABLE 39 REST OF WORLD SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 40 REST OF WORLD SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 41 MIDDLE EAST AND AFRICA SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 42 MIDDLE EAST AND AFRICA SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 43 LATIN AMERICA SORAFENIB MARKET, BY PRODUCT, 2020 - 2027 (USD MILLION)
  • TABLE 44 LATIN AMERICA SORAFENIB MARKET, BY APPLICATION, 2020 - 2027 (USD MILLION)
  • TABLE 45 COMPANY MARKET RANKING ANALYSIS
  • TABLE 46 BAYER AG: PRODUCT BENCHMARKING
  • TABLE 47 CIPLA: PRODUCT BENCHMARKING
  • TABLE 48 NATCO PHARMA: PRODUCT BENCHMARKING
  • TABLE 49 HETERO HEALTHCARE: PRODUCT BENCHMARKING

LIST OF FIGURES

  • FIGURE 1 GLOBAL SORAFENIB MARKET SEGMENTATION
  • FIGURE 2 RESEARCH TIMELINES
  • FIGURE 3 DATA TRIANGULATION
  • FIGURE 4 MARKET RESEARCH FLOW
  • FIGURE 5 GLOBAL SORAFENIB MARKET OVERVIEW
  • FIGURE 6 GLOBAL SORAFENIB MARKET GEOGRAPHICAL ANALYSIS, 2020-2027
  • FIGURE 7 GLOBAL SORAFENIB MARKET, BY PRODUCT (USD MILLION)
  • FIGURE 8 GLOBAL SORAFENIB MARKET, BY APPLICATION (USD MILLION)
  • FIGURE 9 FUTURE MARKET OPPORTUNITIES
  • FIGURE 10 NORTH AMERICA DOMINATED THE MARKET IN 2019
  • FIGURE 11 GLOBAL SORAFENIB MARKET OUTLOOK
  • FIGURE 12 GLOBAL AGE-STANDARDIZED INCIDENCE RATES OF CANCER IN 2018
  • FIGURE 13 GLOBAL NUMBER OF NEW CASES IN 2018, BOTH SEXES, ALL AGES
  • FIGURE 14 BAYER - NEXAVAR / SORAFENIB SALES
  • FIGURE 15 GLOBAL SORAFENIB MARKET, BY PRODUCT
  • FIGURE 16 GLOBAL SORAFENIB MARKET, BY APPLICATION
  • FIGURE 17 GLOBAL SORAFENIB MARKET, BY GEOGRAPHY, 2020 - 2027 (USD MILLION)
  • FIGURE 18 NORTH AMERICA MARKET SNAPSHOT
  • FIGURE 19 EUROPE MARKET SNAPSHOT
  • FIGURE 20 ASIA PACIFIC MARKET SNAPSHOT
  • FIGURE 21 REST OF WORLD SNAPSHOT
  • FIGURE 22 BAYER AG: COMPANY INSIGHT
  • FIGURE 23 BAYER AG: SEGMENT BREAKDOWN
  • FIGURE 24 BAYER AG: SWOT ANALYSIS
  • FIGURE 25 CIPLA: COMPANY INSIGHTS
  • FIGURE 26 CIPLA: SEGMENT BREAKDOWN
  • FIGURE 27 CIPLA: SWOT ANALYSIS
  • FIGURE 28 NATCO PHARMA: COMPANY INSIGHTS
  • FIGURE 29 NATCO PHARMA: SEGMENT BREAKDOWN
  • FIGURE 30 NATCO PHARMA: SWOT ANALYSIS
  • FIGURE 31 HETERO HEALTHCARE: COMPANY INSIGHT
  • FIGURE 32 HETERO HEALTHCARE: SWOT ANALYSIS